Roy S. Herbst, MD, PhD: In advanced nondriver non—small cell lung cancer, the first thing I would do would be to test for PD-L1. If that’s high—50% or more positivity for PD-L1—for 20% of patients, maybe, 25%, I would give those patients pembrolizumab. The other 75% of patients—outside of a clinical trial, and certainly at Yale Cancer Center, we’re looking for clinical trials—in the absence of a clinical trial, we do platinum-based chemotherapy. Which one to use? Certainly, if the patient has nonsquamous disease, these days we’re using carboplatin/pemetrexed. If someone has squamous disease, of course, pemetrexed is not approved in that setting. Then, you would probably use carboplatin/paclitaxel or maybe carboplatin/gemcitabine. In some cases with carboplatin/paclitaxel, one might want to add bevacizumab, the angiogenesis inhibitor. I would do that if I was using that doublet.
In the frontline setting, PD-L1 expression would be the sole determinant of who would get immunotherapy alone. As far as chemotherapy goes, performance status is critical. If someone has a performance status of 0 or 1, give them a platinum-based therapy. If they have a performance status of 2, I might move away from platinum and just give a single agent. That would be pemetrexed if they’re nonsquamous, and, if they’re squamous, maybe docetaxel. I might even not treat if they’re really in the poor performance status state, but most of those patients would get chemotherapy.
Patients with nonsquamous non—small cell lung cancer, which are the majority of patients, are getting chemotherapy alone. That would be carboplatin/pemetrexed. I will offer maintenance to patients who have a stable disease or response; I usually start to discuss that after 2 cycles. Then, of course, I will offer maintenance, because maintenance has been shown to improve survival.
If someone has squamous lung cancer, I usually don’t do maintenance in that setting. I don’t think the drug docetaxel is as attractive a drug to use—pemetrexed is so much better tolerated. Someday, maybe, we’ll be doing maintenance with immunotherapies or other agents like that. The key to maintenance is added value—added outcome with not a lot of added toxicity. But, usually, I do offer maintenance to the patients with nonsquamous lung cancer.
The option for maintenance in stage 4 disease is pemetrexed. There are some data for erlotinib maintenance, but I think, outside of patients having an EGFR mutation, I wouldn’t use erlotinib in that setting. I really think the only maintenance drug is pemetrexed for the nonsquamous patients. We need better maintenance options. No one is cured with stage 4 metastatic lung cancer, so then the question would be, maybe we want to use an immunotherapy or use something like that? And I think we’re going to start seeing some trials like that in the future.
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What Mass General Brigham Is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More